

## DRUG INTERACTIONS WITH NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddI) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
Usual Dose	300 mg po BID	200 mg po q8h (TID), or 300 mg po BID	150 mg po BID or 300 mg once daily	<i>Buffered tablets (ddI-BT):</i> >60 kg = 200 mg po q12h or 400mg QD; <60 kg = 125 mg po BID or 250mg QD <i>Enteric capsule (ddI-EC):</i> > 60kg =400mg q24h; <60kg = 250mg q24h	0.75 mg po TID	>60 kg: 20-40 mg po BID <60 kg: 15-30 mg po BID
Kinetic Characteristics	18% CSF penetration; hepatic metabolism via alcohol dehydrogenase and glucuronidation pathways.	15-135% (average 60%) CSF penetration; first pass metabolism, hepatic glucuronidation; 14% (parent) and 75% (metabolite) renal elimination.	10% CSF penetration; 70% renal elimination.	Requires basic media for absorption (tablet contains Mg/ Ca buffers); 21% CSF penetration; partially metabolized via hypoxanthine; 30-50% renal elimination.	15-20% CSF penetration; 62-75% renal elimination.	16-72% (average 30%) CSF penetration; not metabolized; 34-43% renal elimination.
Food	Can take with or without food. <sup>7</sup>	Best on an empty stomach. Can take with a non-fatty meal to minimize nausea. Fatty foods result in a 57% ↓ in AZT concentrations. <sup>8</sup>	Can take with or without food. Diabetics should be warned that the solution contains 20g/100ml of sucrose. Solution is now alcohol-free.	<i>Buffered tablets (ddI-BT):</i> ddI AUC ↓ 47% with food; take on empty stomach (30min before or 2 hours after meals). <i>Enteric capsule (ddI-EC):</i>	Best on an empty stomach, but can take with or without food.	Can take with or without food.

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
				<p><i>Reductions in ddl Cmax and AUC<sup>9</sup>):</i></p> <ul style="list-style-type: none"> <li>• High fat meal (↓ 46%, 19%)</li> <li>• Light meal (↓ 22%, 27%)</li> <li>• 1.5 hours before a light meal (15%, 24%)</li> <li>• 2 hours after a light meal (15%, 10%)</li> <li>• with yogurt: (30%, 20%)</li> <li>• with applesauce: (24%, 18%)</li> </ul> <p><b>Administer 1.5 hours before or 2 hours after food.</b></p>		
Acyclovir		Case report of profound lethargy. <sup>10</sup> No drug interaction seen in larger study. <sup>11</sup>				
Alcohol	No disulfiram reaction noted, no change in EtOH PK, 41% ↑ ABC AUC (not clinically significant). <sup>12</sup>					

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
Allopurinol				122% ↑ ddl AUC, 116% ↑ Cmax in healthy subjects. Clinical significance unclear. <sup>13</sup> Allopurinol 300mg/day + ddl buffered tabs 200mg/day resulted in similar ddl AUC as ddl 200mg BID. <sup>14</sup> <b>Combination is contraindicated</b> based on the ↑ potential for ddl- associated toxicity due to increase in didanosine levels. <sup>15</sup>		
Amprenavir (APV)	29% ↑ APV AUC. No change in ABC concentrations. <sup>16</sup> Synergistic activity in vitro. <sup>17</sup>	31% ↑ AZT AUC. 13% ↑ APV AUC No dosage adjustment is required. <sup>18</sup>	No significant interaction. <sup>18</sup>	No significant changes in amprenavir AUC or Cmin observed when administered: concurrently with ddl-EC (in fasting state) concurrently with ddl tablets (in fasting state) 1 hour prior to ddl tablets		

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
				(fasting) compared to amprenavir alone in the fasting state. Authors suggest amprenavir may be dosed concurrently with both ddl tablets and enteric-coated capsules in the fasting state. <sup>19</sup>		
Antacids				May ↑ ddl levels. Additive antacid side-effects (i.e. diarrhea). <sup>20</sup>	25% ↓ ddC levels. Space out by 2 hours. <sup>5</sup>	
Antineoplastics, flucytosine, trimetrexate		Increased hematotoxicity. No significant kinetic interaction with antineoplastics. <sup>21</sup>		Additive neuropathy with vinca alkaloids.	Additive neuropathy with vinca alkaloids.	Additive neuropathy with vinca alkaloids.
Atazanavir		In healthy volunteers (n=20), atazanavir 400 mg daily plus Combivir BID at steady- state did not result in any significant changes to PK parameters of any drug. <sup>22</sup> Atazanavir may be coadministered with zidovudine	In healthy volunteers (n=20), atazanavir 400 mg daily plus Combivir BID at steady- state did not result in any significant changes to PK parameters of any drug. <sup>22</sup> Atazanavir may be coadministered with zidovudine	Simultaneous administration of atazanavir, <b>didanosine tablets</b> and stavudine resulted in 89% ↓ Cmax and 87% ↓ AUC of atazanavir; kinetics of didanosine and stavudine were not		Simultaneous administration of atazanavir, didanosine tablets and <b>stavudine</b> resulted in 89% ↓ Cmax and 87% ↓ AUC of atazanavir (likely due to buffer in ddl tablets); kinetics of didanosine and

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
		and lamivudine without dosage adjustment.	and lamivudine without dosage adjustment.	affected. When atazanavir was administered 1 hour apart from didanosine, atazanavir concentrations were not affected. Recommend taking ddl-tablets 30 minutes before or 2 hours after atazanavir (which is taken with food). <sup>23</sup> <b>ddl-EC</b> should be given 1.5 hours before or 2 hours after atazanavir (which is taken with food).		stavudine were not affected. <sup>23</sup>  No dosage adjustment required for simultaneous administration of d4T and atazanavir.
Atovaquone		35% ↑ AZT AUC. No dosage adjustment recommended. Monitor for AZT toxicity. <sup>24</sup>				
Azithromycin		10% ↑ in AZT AUC. No dosage adjustment recommended. <sup>25</sup>				
Cimetidine		Inhibition of AZT clearance, however dosage adjustment not		May ↑ ddl levels. Monitor for ddl toxicity.	36% ↑ ddC AUC. Give ddC 2 hours before cimetidine,	

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
		warranted. <sup>26</sup>			or use sucralfate instead. <sup>5</sup>	
Clarithromycin		10-25% ↓ AZT AUC. Consider spacing out administration by 2 hours. Monitor for AZT efficacy. <sup>27</sup>				
Dapsone		↑ hematotoxicity; dapsone induced methemoglobinemia in mouse model. <sup>28</sup>		Early reports of dapsone failure, <sup>29</sup> however no kinetic interaction. <sup>30</sup> Spacing of doses is not required. Additive neuropathy.	20% ↓ dapsone clearance. <sup>31</sup> Additive neuropathy.	Additive neuropathy.
Darunavir	No drug interaction expected, based on different elimination pathways (i.e., renal excretion) of NRTIs (Prezista Product Monograph, 2006).	No drug interaction expected, based on different elimination pathways (i.e., renal excretion) of NRTIs (Prezista Product Monograph, 2006).	No drug interaction expected, based on different elimination pathways (i.e., renal excretion) of NRTIs (Prezista Product Monograph, 2006).	In healthy volunteers, didanosine 400 mg QD on an empty stomach and darunavir 600 mg/ritonavir 100 mg BID with food (2 hours after ddl intake) did not significantly affect plasma levels of either drug. No dosage adjustment is required. <sup>32</sup>	No drug interaction expected, based on different elimination pathways (i.e., renal excretion) of NRTIs (Prezista Product Monograph, 2006).	No drug interaction expected, based on different elimination pathways (i.e., renal excretion) of NRTIs (Prezista Product Monograph, 2006).
Delavirdine (DLV)		No kinetic interaction. <sup>33</sup>		37% ↓ DLV AUC and 22% ↓ ddl		

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
		Additive-synergistic effect in vitro with combination. <sup>33</sup>		AUC. Give DLV 1 hour before ddl if possible. <sup>33, 34</sup>		
Didanosine (ddl)		19% ↓ ddl AUC; 35% ↑ AZT AUC. No dosage adjustments required. <sup>35</sup> Another study showed no interaction. <sup>36</sup>			Additive toxicities. <b>Avoid combination.</b> <sup>5, 37</sup>	No kinetic interaction. <sup>38</sup> Additive neuropathy.
Efavirenz	No significant interaction. <sup>39</sup>	No significant interaction. <sup>40</sup>	No significant interaction. <sup>40</sup>	EFV does not interact with antacids, therefore ddl buffer should not interfere with EFV absorption. <sup>40</sup>		
Elvitegravir (GS-9137)	In healthy subjects, elvitegravir 200 mg/ritonavir 100 mg QD did not have significant effects on the kinetics of single dose abacavir, and vice versa. No dose adjustments of elvitegravir are required. <sup>41</sup>	In healthy subjects, elvitegravir 200 mg/ritonavir 100 mg QD did not have significant effects on the kinetics of multi-dose zidovudine, and vice versa. No dose adjustments of elvitegravir are required. <sup>41</sup>		In healthy subjects, elvitegravir 200 mg/ritonavir 100 mg QD plus single dose didanosine resulted in 14% ↓ AUC and 25% ↓ Cmin of didanosine, while elvitegravir exposure was not significantly altered. No dose adjustments of elvitegravir are		In healthy subjects, elvitegravir 200 mg/ritonavir 100 mg QD did not have significant effects on the kinetics of single dose stavudine and vice versa. No dose adjustments of elvitegravir are required. <sup>41</sup>

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
				required. <sup>41</sup>		
Emtricitabine (FTC)		Prospective, single-dose kinetic study in healthy volunteers of 200 mg FTC plus 300 mg zidovudine resulted in 26% ↑ AUC and 66% ↑ C <sub>max</sub> of zidovudine. FTC kinetics were unchanged. Clinical significance unknown, but dosage adjustments may not be needed. <sup>42</sup>				Prospective, single-dose kinetic study in healthy volunteers of 200 mg FTC plus 40 mg stavudine resulted in no change in kinetics of either drug. Dosage adjustments not required. <sup>42</sup>
Fexofenadine				May ↓ fexofenadine absorption. Give fexofenadine 2 hours before or after ddl. <sup>43</sup>		
Foscarnet		Increased risk of anemia. <sup>44</sup>				
Fluconazole		74% ↑ AZT AUC. Monitor for AZT toxicity. <sup>45</sup>		No kinetic interaction with either ddl-BT or ddl-EC. <sup>46, 47</sup>		No kinetic interaction. <sup>48</sup>
Ganciclovir (GCV)		Additive hematotoxicity		<u>PO GCV:</u> >100% ↑ ddl AUC and		

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
*see also Valganciclovir		which can be serious. Best to avoid combination, or use lower doses of AZT during GCV induction therapy. <sup>49</sup> <u>PO GCV:</u> 19.5% ↑ AZT AUC; no change in GCV AUC. <sup>50</sup>		23% ↓ ganciclovir AUC ( <i>if ddl given 2 hours before GCV</i> ) & no effect on GCV AUC ( <i>ddl given at same time as GCV</i> ). Consider administration of PO GCV at the same time as ddl. <sup>50, 51</sup> <u>IV GCV:</u> >70% ↑ ddl AUC. <sup>52</sup> For both IV and PO GCV, monitor for ddl toxicity (pancreatitis, neuropathy). <sup>15</sup> Mechanism possibly related to phosphorylated GCV metabolite inhibition of purine nucleoside phosphorylase enzyme (PNP), which is responsible for ddl breakdown. <sup>53</sup>		
GS9137 (integrase inhibitor)		No clinically relevant drug interaction observed when	No clinically relevant drug interaction observed when			

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
		healthy subjects (n=24) received GS-9137 200 mg/rtv 100 mg QD with or without zidovudine 300 mg BID. <sup>54</sup>	healthy subjects (n=24) received GS-9137 50 mg/rtv 100 mg QD with or without <b>emtricitabine 200 mg/tenofovir 300 mg QD.</b> <sup>55</sup>  As such, no significant interaction is expected between lamivudine and GS-9137/ritonavir.			
Indinavir (IDV)	No significant interaction. <sup>39</sup>	13% ↑ IDV AUC; 17% ↑ AZT AUC. No dosage adjustment is required. <sup>56</sup>		84% ↓ IDV AUC. Administer indinavir ≥ 1 hour prior to ddl-BT. <sup>20, 57</sup>  Enteric coated formulation of didanosine (ddl-EC) may be coadministered with indinavir. <sup>9</sup>		25% ↑ d4T AUC. Monitor for d4T toxicity. <sup>56</sup>  Prospective study in healthy volunteers of d4T 40 mg single plus indinavir 800mg resulted in no significant changes in d4T AUC or Cmax. When d4T was coadministered with indinavir 800 mg/ritonavir 200 mg, d4T Cmax was unchanged, while d4T AUC ↑

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
						24%; this was not felt to be clinically significant, and no dosage adjustments are recommended. <sup>58</sup>
Itraconazole		No significant interaction. <sup>59</sup>		Undetectable itraconazole levels (capsules only). Give itraconazole 2 hours before or after ddl-BT. <sup>60</sup> No change in itraconazole concentration when co-administered with ddl-EC. <sup>47</sup>		
Ketoconazole				May reduce ketoconazole levels. Give ketoconazole 2 hours before or after ddl. <sup>20</sup> Enteric coated formulation of didanosine (ddl-EC) may be coadministered with ketoconazole. <sup>9</sup>		
Lamivudine (3TC)	15% ↓ 3TC AUC. No change in ABC levels. <sup>61</sup>	No significant kinetic interaction. <sup>3</sup> Case reports of			Antagonism. <b>Avoid combination.</b> <sup>65</sup>	No kinetic interaction. <sup>6</sup>

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
		profound anemia with combination. <sup>62, 63</sup> 3TC may resensitize AZT to HIV. <sup>64</sup>				
Lopinavir/ ritonavir						
Maraviroc		Maraviroc had no effect on the pharmacokinetics of zidovudine. <sup>66</sup>	Maraviroc had no effect on the pharmacokinetics of lamivudine. <sup>66</sup>			
Methadone (oral)  Other opioid dependence therapies LAAM (l-alpha-acetylmethadol), buprenorphine, naltrexone	↓ ABC Cmax, ↑ Tmax, likely not clinically significant; minor ↑ methadone clearance with ABC. <sup>67</sup>	41% ↑ AZT levels. Monitor for AZT toxicity. <sup>68</sup>  No significant interaction seen with LAAM (l-alpha-acetylmethadol), buprenorphine, naltrexone. <sup>69</sup>		41% ↓ ddl AUC. Significance of interaction unknown. <sup>70</sup>  Analysis of methadone's effect on ddl exposure showed that ddl Cmax and AUC ↓ less than 20% with the enteric coated capsules, while ddl Cmax ↓ 40% and AUC ↓ 30% when given as buffered tablets. Since formulation characteristics for the pediatric powder and the buffered tablet are		27% ↓ d4T AUC. Significance of interaction unknown, but may require higher doses of d4T. <sup>70</sup>

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
				similar, <b>do not coadminister methadone with ddl pediatric powder</b> due to significant ↓ in ddl concentrations. If coadministration of methadone and didanosine is necessary, use ddl EC formulation and monitor for HIV clinical response. <sup>15</sup>		
Mycophenolate mofetil (MMF) ( <i>active metabolite, mycophenolic acid: GT</i> )			In a small case series (n=6) of HIV+ subjects receiving ddl, 3TC, abacavir, indinavir 800/ ritonavir 100 mg BID and nevirapine 200 mg BID, there was no significant change in intracellular abacavir TP concentrations in the presence of chronic MMF administration. <sup>71</sup>	MMF absorption may be decreased in the presence of antacids containing magnesium and aluminum.  Administer MMF at least 1 hour prior or 2 hours after ddl buffered tablets.		
Nelfinavir		35% ↓ AZT AUC. Monitor for AZT efficacy. <sup>72</sup>	10% ↑ 3TC AUC. <sup>72</sup>	No interaction, however NFV should be given with food, and ddl		No significant interaction. <sup>72</sup>

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
				on an empty stomach. <sup>72</sup>		
Nevirapine (NVP)		32% ↓ AZT AUC. Monitor for AZT efficacy. <sup>73</sup>	No significant interaction. <sup>74</sup>	No significant interaction. <sup>75, 76</sup>	No significant interaction. <sup>75, 76</sup>	
NSAIDS (i.e. naproxen, indomethacin)		Neither indomethacin nor naproxen significantly affect AZT levels. <sup>77, 78</sup>				
Pentamidine		Increased hematotoxicity.	Additive pancreatotoxicity.	Additive pancreatotoxicity. Due to prolonged half-life of pentamidine, do not restart didanosine until one week after pentamidine therapy is concluded. <sup>79</sup> Monitor amylase, lipase monthly. <b>Avoid combination if possible</b>	Additive pancreatotoxicity. Due to prolonged half-life of pentamidine, do not restart zalcitabine until one week after pentamidine therapy is concluded. <sup>79</sup> Monitor amylase, lipase monthly. <b>Avoid combination if possible</b>	Additive pancreatotoxicity. Due to prolonged half-life of pentamidine, do not restart stavudine until one week after pentamidine therapy is concluded. <sup>79</sup> Monitor amylase, lipase monthly. <b>Avoid combination if possible</b>
Phenytoin		30% ↓ AZT clearance. Monitor for AZT toxicity. <sup>2</sup>				
Probenecid		80% ↑ AZT AUC. Consider reducing AZT dosage. Monitor for AZT toxicity, rash, and			50% ↑ ddC AUC. Monitor for ddC toxicity. May require ddC dose	

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
		flu-like symptoms. <sup>80</sup>			reduction. <sup>5</sup>	
Pyrazinamide (PZA)		Potential ↓PZA AUC and efficacy. Clinical significance unknown. <sup>81</sup>				
Quinolones (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin)				98% ↓ ciprofloxacin AUC. Give ciprofloxacin 2 hours before or 6 hours after ddl. <sup>82, 83</sup> Enteric coated formulation of didanosine (ddl- EC) may be co- administered with ciprofloxacin. <sup>9</sup>		
Ribavirin	Ribavirin is a guanosine analogue. Theoretically, ribavirin and abacavir may compete for intracellular phosphorylation, possibly reducing anti-HCV activity of ribavirin.  Some controversy exists whether concomitant	In vitro, ribavirin may antagonize AZT via competition for phosphorylation. <sup>91</sup> In vivo, a case series failed to show increased viral loads with patients on HAART, suggesting that AZT may be used with ribavirin. <sup>92</sup> In a prospective kinetic study,	In a prospective kinetic study, ribavirin 800 mg/daily did not affect the intracellular phosphorylation or plasma kinetics of ZDV, 3TC, or d4T in HCV/HIV-co- infected patients when assessed after 8-12 weeks of co- administration. <sup>93</sup>	<i>In vitro</i> , ribavirin ↑ levels of active ddl metabolite, dideoxyadenosine 5'-triphosphate (ddATP). Potential for ↑ mitochondrial toxicity (i.e. pancreatitis, hyperlactatemia, fatal lactic acidosis, peripheral neuropathy). <sup>4, 96-98</sup> <sup>99</sup>		In vivo, a case series failed to demonstrate increased viral loads with patients on HAART, suggesting that d4T may be used with ribavirin. <sup>92</sup> In a prospective kinetic study, ribavirin 800 mg/daily did not affect the intracellular phosphorylation or

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
	<p>abacavir therapy may be associated with a reduced response to pegylated interferon and ribavirin,<sup>84-86</sup> but a recent in vitro study showed that the anti-HCV activity of ribavirin was not modified by abacavir<sup>87</sup>. Achieving adequate ribavirin trough levels via weight-based dosing should overcome any potential negligible effect of abacavir,<sup>88, 89</sup> and there is insufficient evidence to recommend avoiding this combination.<sup>90</sup></p>	<p>ribavirin 800 mg/daily did not affect the intracellular phosphorylation or plasma kinetics of ZDV, 3TC, or d4T in HCV/HIV-co-infected patients when assessed after 8-12 weeks of co-administration.<sup>93</sup></p> <p><b>However, potential for ↑ mitochondrial toxicity (e.g., lactic acidosis) &amp; hematotoxicity.</b></p> <p>In a cohort of 50 HIV/HCV subjects on HAART who started pegylated interferon and weight-adjusted ribavirin, 8/20 (40%) on concomitant AZT developed grade 1 or higher anemia, versus 4/30 (13.3%) of those not on AZT, p=0.04.<sup>94</sup></p>		<p>Given availability of other NRTIs and the concern for potential didanosine-induced hepatotoxicity in patients with underlying liver disease (those receiving ribavirin as part of Hepatitis C treatment), the <b>coadministration of ribavirin and didanosine is now contraindicated.</b><sup>1</sup></p> <p><sup>5</sup></p>		<p>plasma kinetics of ZDV, 3TC, or d4T in HCV/HIV-co-infected patients when assessed after 8-12 weeks of co-administration.<sup>93</sup></p> <p><b>Avoid combination if possible. Potential for ↑ mitochondrial toxicity (i.e. pancreatitis, lactic acidosis).<sup>96-98</sup></b></p>

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
		<b>Therefore, avoid combination whenever possible;<sup>95</sup> otherwise, close monitoring for toxicity is recommended.</b>				
Rifabutin		32% ↓ AZT AUC. May require higher AZT doses. <sup>100</sup>		Kinetic study showed no significant interaction. <sup>101</sup> However, case report of undetectable rifabutin levels when co-administered with once daily ddl-BT, due to ↑ amount of buffer. Separate once daily ddl-BT from rifabutin by at least 2 hrs to avoid interaction. <sup>102</sup>		No significant interaction. <sup>48</sup>
Rifampin		48% ↓ AZT AUC. and 89% ↑ AZT clearance. May require higher AZT doses. <sup>2, 103, 104</sup>	Population pharmacokinetics of 3TC in 16 HIV-positive subjects were similar before and during rifampin-based therapy for tuberculosis.			

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddI) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
			Interaction unlikely to be of clinical significance. <sup>105</sup>			
Rilpivirine				No dose adjustment is required. However, didanosine should be administered on an empty stomach at least 2 hours before or 4 hours after rilpivirine, which should be administered after a meal. <sup>106</sup>		
Ritonavir		25% ↓ AZT AUC. Dosage adjustment not recommended. <sup>107, 108</sup>		13% ↑ ddI AUC. Space out by 2.5 hours due to potential formulation incompatibilities. <sup>20, 107, 109</sup>		Prospective study in healthy volunteers of d4T 40 mg single dose plus indinavir 800 mg/ritonavir 200 mg resulted in unchanged d4T C <sub>max</sub> , while d4T AUC ↑ 24%; this was not felt to be clinically significant, and no dosage adjustments are recommended. <sup>58</sup>
Saquinavir		No significant interaction. <sup>110</sup>			No significant interaction. <sup>110</sup>	

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddl) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
Stavudine (d4T)		Antagonism. <b>Avoid combination.</b> <sup>6, 111</sup>	No significant interaction. <sup>6</sup>	No kinetic interaction. <sup>38</sup> Additive neuropathy.	Additive neuropathy.	
Tenofovir	See separate table for tenofovir drug interactions.					
Tetracycline				May ↓ tetracycline levels. Give tetracycline 2 hours before or after ddl. <sup>20</sup>		
Tipranavir	Abacavir ↓ 35-44%. Appropriate doses for the combination of ABC and TPV/r have not been established.	The addition of <b>tipranavir 900, 1200 or 1500 mg TID</b> to stable AZT 300 mg BID (n=16) resulted in 46% ↓ AZT AUC (p<0.01); investigators concluded this was not clinically significant. <sup>112</sup>  Healthy volunteer, randomized, parallel group study (n=60) of either <b>TPV/r 500 mg/100 mg or TPV/r 750 mg/200 mg</b> plus AZT 300 mg BID. At steady state,	The addition of <b>tipranavir 900, 1200 or 1500 mg TID</b> to a stable regimen of 3TC 150 mg BID (n=30) resulted in 27% ↓ 3TC AUC (p<0.01); investigators concluded that this was not clinically significant. <sup>112</sup>	The addition of <b>tipranavir 900, 1200 or 1500 mg TID</b> to a stable regimen of <b>ddl tablets 200 mg</b> BID (n=4) resulted in 46% ↓ ddl AUC (p=0.22). Investigators concluded that this difference was not clinically significant. <sup>112</sup>  Healthy volunteer, randomized, parallel group study (n=23) of either <b>TPV/r 500 mg/100 mg or TPV/r 750 mg/200 mg</b> plus <b>ddl EC</b>		The addition of <b>tipranavir 900, 1200 or 1500 mg TID</b> to a stable regimen of d4T 40 mg BID (n=15) resulted in 15% ↓ d4T AUC (p<0.02). Investigators concluded that this difference was not clinically significant. <sup>112</sup>

	Abacavir (ABC) Ziagen® <sup>1</sup>	Zidovudine (AZT) Retrovir® <sup>2</sup>	Lamivudine (3TC) 3TC® <sup>3</sup>	Didanosine (ddl) Videx®, Videx EC® <sup>4</sup>	Zalcitabine (ddC) Hivid® <sup>5</sup>	Stavudine (d4T) Zerit® <sup>6</sup>
		TPV/r caused a 56%–61% ↓ in ZDV Cmax and a 33%–43% ↓ in AUC. ZDV did not affect the PK of TPV/r. <sup>113</sup>  Appropriate doses for the combination of ZDV and TPV/r have not been established.		400 mg daily. At steady state, 32% ↑ Cmax and 34% ↓ C12h of TPV, although overall TPV AUC unchanged; no change in ddl PK observed. <sup>113</sup> <b>Suggest giving ddl EC 2 hours apart from TPV/r.</b>		
Trimethoprim-Sulfamethoxazole		23% ↑ in AZT AUC due to TMP component. May be more pronounced in hepatic failure. Monitor for AZT toxicity. <sup>114</sup>	43% ↑ 3TC AUC. No dosage adjustment required. Monitor for 3TC side-effects (i.e. GI, headache, fatigue, myalgias, ↓ ANC). <sup>115</sup>			
Valganciclovir				Case report of acute pancreatitis with combination. Given significant interaction with ddl and ganciclovir, caution is warranted with this combination. <sup>116</sup>		
Valproic acid		80% ↑ AZT AUC. <sup>117</sup> Use together with				

	<b>Abacavir (ABC) Ziagen®<sup>1</sup></b>	<b>Zidovudine (AZT) Retrovir®<sup>2</sup></b>	<b>Lamivudine (3TC) 3TC®<sup>3</sup></b>	<b>Didanosine (ddI) Videx®, Videx EC®<sup>4</sup></b>	<b>Zalcitabine (ddC) Hivid®<sup>5</sup></b>	<b>Stavudine (d4T) Zerit®<sup>6</sup></b>
		caution, and monitor for AZT toxicity; severe anemia has been reported with combination secondary to increased levels of AZT. <sup>118</sup>				
Zalcitabine (ddC)		No significant interaction. <sup>5</sup>	Antagonism. <b>Avoid combination.</b> <sup>65</sup>	Additive toxicities. <b>Avoid combination</b> <sup>5, 37</sup>		Additive neuropathy.
Zidovudine (AZT)	24% ↑ AZT AUC. No change in ABC levels. <sup>61</sup>		No significant kinetic interaction. <sup>3</sup> Case reports of profound anemia with combination. <sup>62, 63</sup> 3TC may resensitize AZT to HIV. <sup>64</sup>	19% ↑ ddI AUC; 35% ↓ AZT AUC. No dosage adjustments required. <sup>35</sup>	No significant interaction. <sup>5</sup>	Antagonism. <b>Avoid combination.</b> <sup>6, 111</sup>

Please note: This chart summarizes some of the major drug interactions identified to date, based on current available data; other drug interactions may exist. Please use caution whenever adding/modifying therapy. The information in this table is intended for use by experienced physicians and pharmacists. It is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Due to the rapidly changing nature of information about HIV treatment and therapies, users are advised to recheck the information contained herein with the original source before applying it to patient care.

#### References:

1. Glaxo Wellcome Inc. Ziagen Product Monograph. 2001.
2. Glaxo Wellcome Inc. Retrovir Product Monograph. 2000.
3. Glaxo Wellcome Biochem Inc. 3TC Product Monograph. Mississauga, Ontario, Canada 2001.

Prepared by Michelle Foisy, Pharm.D., Royal Alexandra Hospital, Edmonton, Alberta  
Updated by Michelle Foisy & Alice Tseng, Pharm.D., Toronto General Hospital, ON

July 20, 2011

Page 21 of 30  
www.hivclinic.ca

4. Bristol-Myers Squibb Canada Inc. Videx Product Monograph. 2002.
5. Hoffmann-LaRoche Ltd. Hivid Product Monograph. 2001.
6. Bristol-Myers Squibb Canada Inc. Zerit Product Monograph. 1999.
7. Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. *Pharmacotherapy* 1999;19:932-42.
8. Unadkat JD, Collier AC, Crosbys S, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. *AIDS* 1990;4:229-32.
9. Damle BD, Mummaneni V, Kaul S, et al. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. *Antimicrobial Agents and Chemotherapy* 2002;46:385-91.
10. Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS [letter]. *New England Journal of Medicine* 1987;317:547.
11. Hollander H, Lifson AR, Maha M, et al. Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals. *American Journal of Medicine* 1989;87(6):628-32.
12. McDowell JA, Chittick GE, Pilati-Stevens C, et al. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. *Antimicrobial Agents and Chemotherapy* 2000;44:1686-90.
13. Liang D, Breaux K, Rodriguez-Barradas M, et al. Allopurinol increases didanosine absorption in HIV-infected patients [abstract A498]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL.
14. Boelaertt JR, Dom GM, Huitema ADR, et al. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. *AIDS* 2002;16(16):2221-3.
15. Bristol-Myers Squibb Company. Videx (didanosine) Prescribing Information. Princeton, NJ 2009.
16. GlaxoSmithKline. Agenerase (amprenavir) Agenerase Capsules & Oral Solution Product Monograph. Mississauga 2004.
17. Bilello JA, Bilello PA, Symonds W, et al. Amprenavir (141W94) in combination with 1592U89 is highly synergistic in vitro [abstract I-21]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego.

18. Sadler BM, Gillotin C, Chittick GE, et al. Pharmacokinetic drug interactions with amprenavir [abstract 12389]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland.
19. Shelton MJ, Giovanniello AA, Cloen D, et al. Effects of didanosine formulations on the pharmacokinetics of amprenavir. *Pharmacotherapy* 2003;23(7):835-42.
20. Bristol-Myers Squibb Canada Inc. Videx Product Monograph. 2001.
21. Toffoli G, Errante D, Corona G, et al. Interactions of antineoplastic chemotherapy with zidovudine pharmacokinetics in patients with HIV-related neoplasms. *Chemotherapy* 1999;45:418-28.
22. Mummaneni V, Randall D, Geraldine M, et al. Steady-state pharmacokinetic interaction study of atazanavir with lamivudine and zidovudine in healthy subjects [abstract H1713]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA.
23. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple-dose pharmacokinetic, food effect, and drug interaction studies in healthy subjects [abstract 504]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco.
24. Lee BL, Tauber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. *Clinical Pharmacology and Therapeutics* 1996;59:14-21.
25. Pfizer Canada Inc. Zithromax Product Monograph. 2001.
26. Fletcher CV, Henry WK, Noormohamed SE, et al. The effect of cimetidine and ranitidine administration with zidovudine. *Pharmacotherapy* 1995;15(6):701-8.
27. Polis MA, Piscitelli SC, Vogel S, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. *Antimicrobial Agents & Chemotherapy* 1997;41(8):1709-14.
28. Freund YR, Dousman L, Riccio ES, et al. Immunohematotoxicity studies with combinations of dapsone and zidovudine. *International Immunopharmacology* 2001;1(12):2131-41.
29. Metroka CE, McMechan MR, Andrada R, et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine [letter]. *New England Journal of Medicine* 1991;325:737.
30. Sahai J, Garber G, Gallicano K, et al. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. *Annals of Internal Medicine* 1995;123:584-7.

31. Taburet A, Singlas E. Drug interactions with antiviral drugs. *Clinical Pharmacokinetics* 1996;30(5):385-401.
32. Sekar V, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine [abstract WEPEB012]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 22-25, 2007, Sydney, Australia.
33. Agouron Pharmaceuticals Canada Ltd. Rescriptor (delavirdine) Prescribing Information. Mississauga, Ontario 2001.
34. Morse GD, Fischl MA, Shelton MJ, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. *Antimicrobial Agents and Chemotherapy* 1997;41:169-74.
35. Barry M, Howe JL, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with acquired immunodeficiency syndrome. *British Journal of Clinical Pharmacology* 1994;37:421-6.
36. Sahai J, Gallicano K, Seguin I, et al. Interaction between zidovudine (ZDV) and didanosine (ddI) [abstract 82]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4-7, 1994, New Orleans.
37. LeLacheur SF, Simon GL. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. *Journal of the Acquired Immune Deficiency Syndrome* 1991;4:538-9.
38. Seifert RD, Stewart MB, Sramek JJ, et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. *British Journal of Clinical Pharmacology* 1994;38:405-10.
39. Dicenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. *antimicrobial Agents and Chemotherapy* 2003;47(6):1929-35.
40. Dupont Pharma. Efavirenz (Sustiva) Product Monograph. Mississauga, ON 2000.
41. Ramanathan R, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir *J Acquir Immune Defic Syndr* 2007;46(2):160-66.
42. Wang LH, Blum MR, Hui J, et al. Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers [abstract A 505]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL.
43. Hoechst Marion Roussel. Allegra Product Monograph. 2000.
44. Astra Pharmaceutical Products Inc. Foscavir Product Monograph. Westborough, MA 2000.

45. Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus [see comments]. *Journal of Infectious Diseases* 1994;169(5):1103-7.
46. Bruzzese VL, Gillum JG, Israel DS, et al. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. *Antimicrobial Agents and Chemotherapy* 1995;39:1050-3.
47. Damle B, Hess H, Kaul S, et al. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. *Biopharm Drug Disposition* 2002;23(2):59-66.
48. Piscitelli SC, Kelly G, Walker RE, et al. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 1999;43(3):647-50.
49. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. *Annals of Internal Medicine* 1990;113(2):111-7.
50. Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. *Journal of the Acquired Immune Deficiency Syndrome* 1998;17(3):227-34.
51. Jung D, Griffy K, Dorr A, et al. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. *Journal of Clinical Pharmacology* 1998;38(11):1057-62.
52. Frascino RJ, Gaines Griffy K, Jung D, et al. Multiple dose crossover study of IV ganciclovir induction dose (5 mg/kg IV q12h) and didanosine (200 mg po q12h) in HIV-infected persons [abstract A-27]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco.
53. Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir or tenofovir. *Antimicrob Agents Chemother* 2004;48:1089-95.
54. Ramanathan S, Lagan K, Plummer A, et al. Lack of clinically relevant drug-drug interaction between the ritonavir-boosted HIV integrase inhibitor GS-9137 and zidovudine [abstract TUPE0088]. XVI International AIDS Conference, August 13-18 2006, Toronto, Canada.
55. Ramanathan S, Skillington J, Plummer A, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 and emtricitabine/tenofovir disoproxil fumarate [abstract TUPE0080]. XVI International AIDS Conference August 13-18 2006, Toronto, Canada.
56. Merck Frosst Canada & Co. Crixivan Product Monograph. 2001.
57. Shelton MJ, Mei JH, Hewitt RG, et al. If taken 1 hour before indinavir, didanosine does not affect indinavir exposure, despite persistent buffering effects. *Antimicrobial Agents and Chemotherapy* 2001;45:298-300.

58. Kaul S, Agarwala S, Hess H, et al. The effect of coadministration of indinavir and ritonavir on the pharmacokinetics of stavudine [abstract A1825]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA.
59. Janssen-Ortho Inc. Sporanox Product Monograph. 2001.
60. May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. *Pharmacotherapy* 1994;14:509-13.
61. Symonds WT, McDowell J, Chittick G, et al. The safety and pharmacokinetics of GW159U89, zidovudine (ZDV) and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients [abstract P19]. *AIDS* 1996;10(Suppl 2):S23.
62. Hester EK, Peacock JE. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. *AIDS* 1998;12:439-51.
63. Tseng A, Fletcher D, Gold W, et al. Precipitous declines in hemoglobin with combination AZT/3TC. 4th National Conference on Retroviruses and Opportunistic Infections, January, 1997, Washington.
64. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. *Science* 1995;269(5224):696-9.
65. Veal GJ, Hoggard PG, Barry MG, et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation [letter]. *AIDS* 1996;10:546-8.
66. Pfizer Labs. SELZENTRY (maraviroc) Prescribing Information. New York, NY 2007.
67. Sellers E, Lam R, McDowell J, et al. The pharmacokinetics of abacavir and methadone following coadministration: CNA1012 [abstract 663]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA.
68. McCance-Katz EF, Rainey PM, P PJ, et al. Methadone effects on zidovudine disposition (AIDS clinical trials group 262). *Journal of the Acquired Immune Deficiency Syndrome* 1998;18:435-43.
69. McCance-Katz EF, Rainey PM, Friedland G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. *American Journal of Addictions* 2001;10(4):296-307.
70. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. *Journal of the Acquired Immune Deficiency Syndrome* 2000;24(3):241-8.

71. Martorell J, Brunet M, García F, et al. Mycophenolate mofetil lowers plasma nevirapine concentrations but has no effect on intracellular triphosphate concentrations [abstract 539]. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, MA.
72. Agouron Pharmaceuticals Canada Ltd. Viracept Product Monograph. 2000.
73. Boehringer Ingelheim (Canada) Ltd. Viramune Product Monograph. 2001.
74. Leitz G, Lamson M, Lionetti D, et al. Nevirapine/lamivudine drug-drug interaction study in HIV infected patients [abstract 12217]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland.
75. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. *Expert Opinion on Investigational Drugs* 1996;5:1183-99.
76. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. *Annals of Internal Medicine* 1996;124:1019-30.
77. Sahai J, Gallicano K, Garber G, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. *Clinical Pharmacology and Therapeutics* 1992;52:464-70.
78. Barry M, Howe J, Back D, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. *British Journal of Clinical Pharmacology* 1993;36:82-5.
79. Foisy MM, Slayter KL, Hewitt RG, et al. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. *Annals of Pharmacotherapy* 1994;28(9):1025-8.
80. Kornhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. *Lancet* 1989;2(8661):473-5.
81. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. *Annals of Pharmacotherapy* 1996;30:919-25.
82. Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. *Clin Pharmacol Ther* 1993;53:292-7.
83. Sahai J. Avoiding the ciprofloxacin-didanosine interaction [letter]. *Ann Intern Med* 1995;123:394-5.
84. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. *Antivir Ther* 2008;13(3):429-37.

85. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. *Antivir Ther* 2008;13(7):953-7.
86. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. *J Antimicrob Chemother* 2008;62(6):1365-73.
87. Van den Eynde E, Quer J, Cubero M, et al. Abacavir co-administration does not interfere with the suppressive activity of ribavirin in an HCV replicon system [abstract 963]. 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, USA.
88. Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. *Antimicrob Agents Chemother* 2010;54(4):1647-9.
89. Rockstroh J, Benhamou Y, Bhagani S, et al. European AIDS Clinical Society (EACS) Guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults: 2009. 2009.
90. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available from: <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>, accessed March 16, 2011.
91. Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. *AIDS Research and Human Retroviruses* 1998;14(18):1661-7.
92. Landau A, Batisse D, Piketty C, et al. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. *AIDS* 2000;14(12):1857-8.
93. Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study *Antimicrob Agents Chemother* 2005 October;49(10):3997-4008.
94. Sherman KE. High frequency of anemia in HCV-HIV coinfecting persons receiving weight-based ribavirin and zidovudine [abstract 67955]. 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11-15, 2005, San Francisco, CA.
95. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. *AIDS* 2002;16:813-28.
96. Hittinger G. Mitochondrial toxicity in HIV/HVC coinfecting patients treated with ribavirin, interferon alpha and antiretroviral therapy [abstract TuPeB4516]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain.

97. Smith DM, Puoti M, Sulkowski M, et al. Symptomatic hyperlactatemia during a large Hepatitis C treatment trial in HIV/HCV co-infected participants on stable antiretroviral therapy [abstract MoOrB1059]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain.
98. García-Benayas T, Blanco F, Barrios A, et al. Weight loss in HIV-infected patients receiving interferon plus ribavirin for chronic hepatitis C [abstract B10369]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain.
99. Bruno R, Sacchi P, Filice G. Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo. *AIDS* 2003;17(18):2674-5.
100. Pharmacia and Upjohn Inc. Mycobutin Product Monograph. 2001.
101. Li RC, Narang' PK, Sahai J, et al. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. *Antimicrobial Agents and Chemotherapy* 1997;41(7):1566-70.
102. Marzolini C, Chave JP, Telenti A, et al. Impaired absorption of rifabutin by concomitant administration of didanosine. *AIDS* 2001;15(16):2203-4.
103. Burger DM, Meenhorst PL, Koks CH, et al. Pharmacokinetic interaction between rifampin and zidovudine. *Antimicrobial Agents and Chemotherapy* 1993;37:1426-31.
104. Gallicano KD, Sahai J, Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. *British Journal of Clinical Pharmacology* 1999;48(2):168-79.
105. Van der Walt J, Cohen K, McIlIeron H, et al. The effect of rifampicin-based tubercular therapy on the population pharmacokinetics of lamivudine [abstract P\_24]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam.
106. Tibotec Inc. Edurant (rilpivirine) Product Monograph. Raritan, NJ 2011.
107. Abbott Laboratories Limited Canada. Norvir (ritonavir) Prescribing Information. Saint-Laurent, QC 2001.
108. Cato Ar, Qian J, Hsu A, et al. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. *Antimicrobial Agents and Chemotherapy* 1998;42(7):1788-93.
109. Cato A, Qian J, Vomvouras S, et al. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infection patients. *Journal of the Acquired Immune Deficiency Syndrome* 1998;18:466-72.
110. Hoffmann-LaRoche Limited. Fortovase Product Monograph. Mississauga, Ontario 2001.

111. Back D, Haworth S, Hoggard P, et al. Drug interactions with d4T phosphorylation in vitro [abstr]. XI International Conference on AIDS, July 1996, 1996, Vancouver.
112. Phillips L, Borin MT, Hopkins NK, et al. The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients [abstract 81]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco.
113. Roszko PJ, Curry K, Brazina B, et al. Standard doses of efavirenz, zidovudine, tenofovir, and didanosine may be given with tipranavir/ritonavir [abstract 865]. 2nd IAS Conference on HIV and Pathogenesis, July 14-17, 2003, Paris, France.
114. Lee BL, Safrin S, Makrides V, et al. Zidovudine, trimethoprim and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. *Antimicrobial Agents and Chemotherapy* 1996;40:1231-6.
115. Moore KHP, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. *Clinical Pharmacology and Therapeutics* 1996;59:550-8.
116. Pecora Fulco PPF, Higginson RTH, Orenstein RO. Acute pancreatitis associated with the concurrent use of valganciclovir and didanosine [abstract B10396]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain.
117. Lertora JJ, Rege AB, Greenspan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. *Clinical Pharmacology and Therapeutics* 1994;56:272-8.
118. Antoniou T, Gough K, Yoong D, et al. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. *Clin Infect Dis* 2004;38(5):e38-40.